Apost-hoc analysis explored the impact of insulin treatment, which is a known riskfactor for TLF after DES-PCI [131], and found IDDM patients (37.7%) had a higherrisk of MACE as compared to NIDDM patients in both treatment groups [132]. The gene discussed is INS; the disease is type 1 diabetes mellitus.